HPV vaccine trial targets oral cancer risk in men with HIV
NCT ID NCT04255849
First seen Feb 01, 2026 · Last updated Apr 24, 2026 · Updated 9 times
Summary
This study tests whether the nine-valent HPV vaccine can prevent persistent oral HPV infections in 700 men living with HIV. Participants receive either the vaccine or a placebo and are followed for up to four years. The goal is to see if the vaccine reduces the risk of HPV-related oral cancers in this high-risk group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Instituto Nacional de Salud Pública, Mexico
Cuernavaca, Morelos, 62209, Mexico
-
Universidade de São Paulo
São Paulo, São Paulo, 05403-911, Brazil
-
University of Puerto Rico AIDS Clinical Trials Unit
San Juan, Purto Rico, 00935, Puerto Rico
Conditions
Explore the condition pages connected to this study.